PLGA NHS Capped, MW 20K (PLGA‑NHS) is an ultra-high‑molecular‑weight, amine‑reactive biodegradable PLGA copolymer functionalized with terminal N‑hydroxysuccinimide (NHS) ester groups. Featuring ultra-rigid structural performance, exceptional morphological stability and ultra-long slow hydrolytic degradation kinetics, this polymer retains high-activity amine-specific covalent conjugation capability. It serves as a high-end reactive building block for ultra-long-cycle sustained drug delivery, high-rigidity implantable nanoparticle functionalization and long-duration advanced biomedical modification research.
Basic Specifications
Alternative Name: PLGA‑NHS, PLGA N‑hydroxysuccinimide Capped
Polymer Composition: Poly(D,L‑lactide‑co‑glycolic acid)‑NHS
Molecular Weight: 20K, Custom
Appearance: White to off‑white solid
Key Features and Benefits
Highly Active Terminal NHS Ester Reactivity: Functionalized with high-purity terminal NHS ester groups, enabling efficient, high-specificity covalent conjugation with primary amine (-NH₂) groups under mild physiological conditions. The reaction forms stable, irreversible amide bonds with minimal non-specific binding and side reactions. It maintains persistent conjugation activity throughout ultra-long degradation cycles, ensuring ultra-stable covalent modification of antibodies, therapeutic proteins, functional peptides and amine-terminated ligands for long-duration biomedical studies.
Ultra-Stable 20K Ultra-High Molecular Weight Performance: The 20K ultra-high molecular weight forms extremely dense polymer chain entanglement, delivering industry-leading structural rigidity, anti-deformation toughness and morphological durability compared to low, medium and conventional high-MW PLGA. It features uniform, ultra-slow hydrolytic degradation behavior, completely eliminating nanoparticle collapse, structural fatigue and premature drug leakage, perfectly suited for ultra-long-cycle sustained-release formulations and high-rigidity implantable carrier fabrication.
Superior Biocompatibility & Ultra-Long Uniform Degradation: Possesses premium physiological biocompatibility and clinical-grade biosafety. The PLGA backbone undergoes mild, homogeneous hydrolysis into endogenous non-toxic lactic acid and glycolic acid over an ultra-long period, with no inflammatory stimulation, tissue irritation or residual toxicity. It fully complies with strict safety standards for ultra-long-term in vivo implantation and translational biomedical research.
Ultra-Long Stable Conjugation Efficiency: Precision terminal NHS capping technology ensures uniform reactive group distribution and long-lasting batch consistency. The robust amide covalent bond exhibits excellent chemical inertness during ultra-long polymer degradation, effectively preventing ligand shedding, functional attenuation and conjugate failure, delivering stable and repeatable results for multi-month long-cycle experiments and formulations.
Implantable-Grade Functional Modification Compatibility: The mild amine-specific reaction mechanism supports flexible post-synthesis functionalization of ultra-stable implantable nanoparticles and long-service-life tissue engineering scaffolds. It perfectly preserves the biological activity of modified biomolecules and carrier structural integrity, adapting to high-standard ultra-long-term implantable biomedical research scenarios.
Applications
Ultra-Long-Cycle Amine‑Specific Bioconjugation: Ideal for ultra-durable covalent modification and immobilization of high-value antibodies, long-acting therapeutic proteins, functional peptides and targeted ligands, supporting persistent biomolecule assembly and multi-month stable biomedical probe preparation.
Multi-Month Sustained Targeted Drug Delivery: Optimized for manufacturing high-rigidity PLGA nanoparticles and microspheres, achieving uniform ultra-long-cycle sustained drug release and stable active targeted delivery, applicable for chronic disease long-acting treatment and multi-month controlled-release formulation development.
Ultra-Stable Implantable Nanoparticle Functionalization: Serves as a premium reactive precursor for advanced implantable carrier surface engineering, stably immobilizing targeting groups to maximize carrier structural durability, long-term in vivo circulation persistence and sustained targeted accumulation efficiency.
Long-Duration Implantable Biomedical Research: Suitable for high-toughness biomaterial modification, ultra-long-cycle sustained-release system construction and persistent long-term biological labeling, providing reliable reactive performance for high-end translational and implantable biomedical research.
Storage and Handling
Storage: Store at –20 °C in a fully sealed, dry, moisture‑proof container. Inert gas sealing is strongly recommended for long‑term storage to prevent NHS ester hydrolysis and preserve polymer reactive activity and structural integrity.
Handling: Strictly avoid moisture intrusion, high‑temperature environments and prolonged air exposure, as NHS groups are highly moisture‑sensitive and prone to deactivation. Avoid repeated freeze‑thaw cycles to maintain stable conjugation efficiency.
PLGA NHS Capped, MW 20K integrates persistent amine-specific NHS reactivity, ultra-high structural rigidity and multi-month ultra-long-cycle degradability, acting as a premium implantable-grade reactive biodegradable polymer for ultra-long-term bioconjugation, multi-month sustained targeted drug delivery and high-durability biomaterial functional modification research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.